Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Chordoma × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 134 Melanoma 110 Breast Neoplasms 88 Squamous Cell Carcinoma of Head and Neck 82 Triple Negative Breast Neoplasms 73 Lung Neoplasms 58 Neoplasm Metastasis 46 Carcinoma, Renal Cell 40 Neoplasms 39 Head and Neck Neoplasms 37 Ovarian Neoplasms 35 Colorectal Neoplasms 35 Pancreatic Neoplasms 33 Carcinoma, Hepatocellular 31 Urinary Bladder Neoplasms 30 Recurrence 30 Carcinoma, Transitional Cell 30 Glioblastoma 29 Stomach Neoplasms 28 Brain Neoplasms 26 Sarcoma 23 Endometrial Neoplasms 22 Prostatic Neoplasms 21 Hodgkin Disease 19 Fallopian Tube Neoplasms 18 Carcinoma, Squamous Cell 18 Adenocarcinoma 17 Uterine Cervical Neoplasms 16 Multiple Myeloma 15 Lymphoma, Large B-Cell, Diffuse 15

Interventions

Nivolumab 5 palbociclib 2 Radiosurgery 2 Protons 2 Proton Therapy 2 Pemetrexed 2 Ipilimumab 2 Imatinib Mesylate 2 tazemetostat 1 relatlimab 1 pembrolizumab 1 camrelizumab 1 apatinib 1 Zoledronic Acid 1 Thiotepa 1 Surveys and Questionnaires 1 Radiotherapy, Intensity-Modulated 1 Photochemotherapy 1 Peripheral Blood Stem Cell Transplantation 1 Panobinostat 1 Melphalan 1 Mastectomy, Segmental 1 Immunoglobulin G 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Disulfides 1 Dihematoporphyrin Ether 1 Dasatinib 1 Cyclophosphamide 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06794645 2025-01-27

Pembrolizumab and Pemetrexed for Progressive Chordoma

Saint John's Cancer Institute

Phase 2 Recruiting

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡